Merck's Idvynso Wins FDA Approval as First Non-INSTI, Tenofovir-Free HIV Regimen After Years of Safety-Driven Redesign
The FDA cleared doravirine/islatravir on April 21, completing a development program that was halted in 2021 over lymphocyte counts and restarted at a lower dose.
Overview
The U.S. Food and Drug Administration approved Idvynso (doravirine/islatravir) on April 21, 2026, making it the first once-daily, two-drug, single-tablet HIV regimen that avoids both integrase strand-transfer inhibitors (INSTIs) and tenofovir — the backbone of the most widely prescribed HIV therapies. The approval, reported by BioPharma Dive, concludes a development program marked by a clinical hold, a complete dose redesign, and ultimately non-inferior efficacy against Gilead’s market-leading three-drug regimen Biktarvy.
What We Know
The Drug and Its Mechanism
Idvynso pairs doravirine — a non-nucleoside reverse transcriptase inhibitor (NNRTI) previously sold under the brand name Pifeltro — with 0.25 mg of islatravir, a next-generation nucleoside reverse transcriptase translocation inhibitor (NRTTI), as confirmed in the FDA NDA approval letter. The combination disrupts HIV replication through two distinct mechanisms: doravirine non-competitively inhibits HIV-1 reverse transcriptase, while islatravir blocks reverse transcriptase translocation and induces delayed chain termination.
The drug is approved for virologically suppressed adults — those already maintaining HIV-1 RNA below 50 copies per milliliter on a stable regimen — who have no history of virologic treatment failure and no known resistance to doravirine. It is not approved as a first-line treatment for patients who have never received antiretroviral therapy, though an NDA expansion for that population is anticipated.
Phase 3 Trial Results
Two randomized Phase 3 trials formed the evidentiary basis for approval. In Trial 052, a double-blind study enrolling 513 virologically suppressed adults, patients were switched either to Idvynso (n=342) or kept on Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, n=171). At Week 48, 1% of participants in each arm had HIV-1 RNA at or above 50 copies per mL, with overall viral suppression rates of 92% on Idvynso versus 94% on Biktarvy — meeting the non-inferiority threshold.
Trial 051, an open-label study of 551 adults, compared switching to Idvynso (n=366) against continuing existing antiretroviral therapy (n=185). Idvynso performed slightly better by this measure: 1% of recipients showed virologic failure versus 5% in the continuation arm, and 96% achieved suppression compared to 92%. Both trials included participants with diverse demographics, including participants over age 65, and together enrolled more than 700 patients across approximately 53 research sites in eight countries.
Why Tenofovir-Free and Non-INSTI Matters
INSTIs — a drug class that includes bictegravir (in Biktarvy), dolutegravir, and cabotegravir — have dominated HIV treatment guidelines for nearly a decade due to their high barrier to resistance. Tenofovir compounds are similarly ubiquitous, appearing in many fixed-dose combination regimens. The near-universal reliance on these two classes, however, creates a clinical gap: patients who develop tolerability issues, drug interactions, or contraindications have limited alternatives that maintain the simplicity of a single daily pill.
Idvynso fills that gap. As BioPharma Dive noted, the drug is approved as a replacement therapy for adults currently managed on another regimen — making it particularly relevant for aging patients where polypharmacy and drug-interaction management complicate long-term HIV care. Cumulative tenofovir exposure has been associated with renal and bone density concerns over time in some patient populations.
A Development Path Reshaped by Safety Concerns
Islatravir’s road to approval was not straightforward. In late 2021, Merck reported a dose-dependent decrease in lymphocyte counts across multiple islatravir trials, prompting the FDA to impose clinical holds in December 2021, as BioPharma Dive reported at the time. The white blood cell reductions — while described by Merck as remaining within the normal range — raised enough concern to halt several programs simultaneously.
Merck discontinued its once-monthly oral islatravir PrEP program entirely and retooled the remaining portfolio around lower doses. In September 2022, the FDA lifted the holds following agreement on a revised trial design. Merck initiated three new Phase 3 trials at reduced islatravir doses, including the studies supporting the current Idvynso approval. The 0.25 mg dose ultimately used in Idvynso is substantially lower than levels that triggered the original lymphocyte signal.
What We Don’t Know
Whether Idvynso can meaningfully compete with Biktarvy in the broader HIV market remains unclear. Analysts quoted by BioPharma Dive characterized the approved maintenance indication as unlikely to displace Gilead’s dominance, with the more significant commercial test coming if and when Merck wins approval for treatment-naive patients. Long-term safety data at the approved dose is still accumulating, and the clinical significance of residual lymphocyte monitoring requirements in real-world use is not yet established.
Analysis
Idvynso’s approval is notable less for immediate market impact than for what it demonstrates about the durability of novel antiviral mechanisms under regulatory pressure. A drug class-defining molecule — islatravir was among the first NRTTIs to reach late-stage trials — survived a significant setback, a complete dose recalibration, and years of additional study to reach patients. The result is a regimen that broadens the available toolkit for HIV clinicians without relying on the same two pharmacological anchors that have defined standard of care since the early 2010s. Whether a large enough patient population needs that alternative to make Idvynso commercially viable is a separate question — but the science underlying the approval represents a meaningful advance in antiretroviral diversity.